Posted on 27/05/2009 in Pharmaceutical Company Financials Takeda will pay Novartis 100 million yen (655,000 pounds) upfront for the exclusive rights to Vaxem Hib.
The latter has developed the product to protect against the Haemophilus Influenzae Type B virus and it has the potential to produce antibodies in youngsters.
Entering the body through airborne droplets found in coughs and sneezes, the germs can cause meningitis, pneumonia, sepsis and epiglottitis.
Under the terms of the agreement, Takeda will be able to develop, manufacture and commercialise combination vaccines outside of Japan.
Novartis has the priority to become partner if the company decides to market variations of Vaxem Hib with other businesses.
As well as the initial sum, which Takeda will pay to Novartis when the product is launched, the former will also give the latter royalties from the sales.
The company said: "Aiming to meet the requirement from the society for preventive vaccines for children, Takeda will continue enhancing the product line-up of vaccines."
Four components currently being focused on are diphtheria, tetanus, pertussis and polio.
In March this year, Takeda signed an agreement with Wyeth to gain the product licence back for Prostap (leuprorelin acetate) in the UK and Ireland.Other news stories from 27/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
